Insulin Transaction Summary Overview — Privium intends to sell 10% of the special purpose vehicle set up to monetize its rights with respect to its generic insulin transaction and its ongoing rights for $50 million. Privium I has the following rights/assets: • 25% of the common equity of Elona Biotechnology (Elona is a sub S corporation with no debt and one class of stock) • Rights to manufacture, market and sell with rights of sublicense for certain products as follows: Products and Territories Product Territory Insulin and Insulin Derivative products including but not limited to: Humulin, Humalog, Novalog, and Lantus. MENA Plus Territorym Oral Insulin and Oral Insulin Derivative products including but not limited to: Humulin, Humalog, Novalog, Lantus, Apidra and any other oral insulin derivatives cloned by Elona Global rights exclusive of United States of America Glucagon MENA Plus Territory Human Growth Hormone MENA Plus Territory (1) MENA Plus Territory is defined as: Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Palestinian territories (the West Bank and Gaza Strip), Qatar, Saudi Arabia, Sudan, Syria, Tunisia, United Arab Emirates, Yemen, India, Pakistan, Bangladesh, African countries, Burma, Cambodia, Laos, Thailand, Vietnam, Peninsular Malaysia, Brunei, East Malaysia, East Timor, Indonesia, the Philippines, Singapore, North Korea, South Korea, Russia, Ukraine, Belarus, Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Turkey, Bulgaria, Brazil, and renegotiation rights to Japan. Privium believes that there are several ways to monetize these assets including: EFTA00777759